СОВРЕМЕННАЯ ТАКТИКА ИММУНОСУПРЕССИВНОЙ ТЕРАПИИ КАК СПОСОБ ФОРМИРОВАНИЯ ТОЛЕРОГЕННОЙ СТРАТЕГИИ ОРГАНИЗМА (НА ПРИМЕРЕ ТРАНСПЛАНТАЦИИ ПЕЧЕНИ)
https://doi.org/10.15825/1995-1191-2012-2-98-109
Аннотация
Об авторах
С. Д. Артамонов
ФГБУ «ФНЦ трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздравсоцразвития России, г. Москва
Д. А. Великий
ФГБУ «ФНЦ трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздравсоцразвития России, г. Москва
Н. А. Онищенко
ФГБУ «ФНЦ трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздравсоцразвития России, г. Москва
М. Е. Крашенинников
ФГБУ «ФНЦ трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздравсоцразвития России, г. Москва
И. М. Иванов
ФГБУ «ФНЦ трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздравсоцразвития России, г. Москва
Л. В. Башкина
ФГБУ «ФНЦ трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздравсоцразвития России, г. Москва
А. О. Никольская
ФГБУ «ФНЦ трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздравсоцразвития России, г. Москва
Список литературы
1. Артамонов С.Д., Онищенко Н.А., Башкина Л.В. и др. Роль систем врожденного и адаптивного иммунитета в развитии деструктивного иммунного ответа организ- ма на аллотрансплантат // Вестник трансплантологии и искусственных органов. 2010. Т. 12, No 3. С. 112–120.
2. Артамонов С.Д., Онищенко Н.А., Башкина Л.В. и др. Система аутотолерантности и ее функционирование при трансплантации аллогенных органов // Вестник трансплантологии и искусственных органов. 2010. Т. 12, No 3. С. 121–128.
3. Бабаева А.Г., Геворкян Н.М., Зотиков Е.А. Роль лим- фоцитов в оперативном изменении программы раз- вития тканей. М.: РАМН, 2009. 107 с.
4. Готье С.В. Иммуносупрессия при трансплантации солидных органов. М.: Триада, 2011. 470 с.
5. Abu-Elmagd K.M., Costa G., Bond G.J. et al. Evolution of the immunosuppressive strategies for theintestinal and multivisceral recipients with specialreference to allograft immunity and achievement of partial tolerance // Euro- pean Society for Organ Transplantation. 2009. Vol. 22. P. 96–109.
6. Adeyi O., Fischer S.E., Guindi M. Liver allograft patho- logy: approach to interpretation of needle biopsies with clinicopathologicalcorrelation // J. Clin. Pathol. 2010.
7. Vol. 63. P. 47–74.
8. Ashton-Chess J., Giral M., Soulillou J-P., Brouard S.
9. Can immune monitoring help to minimize immunosup- pression in kidney transplantation? // Transpl. Int. 2009. Vol. 22. P. 110–119.
10. Azzi J., Sayegh M.H. Clinical transplantation tolerance: a myth no more, but // Am. J. Kidney Dis. 2009. Vol. 54. P. 1005–1011.
11. Bakr M.A. Induction therapy // Experimental and Clini- cal Transplantation. 2005. Vol. 3 (1). P. 320–328.
12. Bishop G.A., Ierino F.L., Sharland A.F., Hall B.M. et al. Approaching the promise of operational tolerance in cli- nical transplantation // Transplantation. 2011. Vol. 91, No 10. P. 1065–1074.
13. Bucuvalas J. Long-term outcomes in pediatric liver trans- plantation // Liver Transplantation. 2009. Vol. 15. P. 6–11.
14. Calne R., Friend P., Moffatt S. et al. Prope tolerance, pe- rioperative campath 1H, and low-dose cyclosporin mo- notherapy in renal allograft recipients // Lancet. 1998.
15. Vol. 351. P. 1701–1702.
16. Carey E., Carey W.D. Noninvasive tests for liver disease,
17. fibrosis, and cirrhosis: Is liver biopsy obsolete? // Cleveland
18. Clinic Journal of Medicine. 2010. Vol. 77 (8). P. 519–527.
19. Charlton M.R., Wall W.J., Ojo A.O. et al. International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society ex- pert panel consensus conference on renal insufficiency in liver transplantation // Liver Transplantation. 2009.
20. Vol. 15. P. 1–34.
21. De Serres S.A., Sayegh M.H., Najafian N. Immunosup-
22. pressive drugs and Tregs: a critical evaluation! // Clin. J.
23. Am. Soc. Nephrol. 2009. Vol. 4. P. 1661–1669.
24. Demetris A.J., Lunz J.G., Randhawa P. et al. Monitoring of human liver and kidney allograft tolerance:a tissue/ histopathology perspective 2008 European Society for
25. Organ // Transplantation. 2009. Vol. 22. P. 120–141.
26. Dousset B., Hubscher S.G., Padbury R.T. et al. Acute liver allograft rejection – is treatment always necessa-
27. ry? // Transplantation. 1993. Vol. 55. P. 529–534.
28. Feng S. Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirableand/or possible? // Curr. Opin. Or-
29. gan Transplant. 2008. Vol. 13 (5). P. 506–512.
30. Ford M.L., Larsen C.P. Translating costimulation blocka- de to the clinic: lessons learned from three pathways //
31. Immunol Rev. 2009. Vol. 229 (1). P. 294–306.
32. Gangappa S., Kokko K.E., Carlson L.M. et al. Immune responsiveness and protective immunity after transplan-
33. tation // Transpl. Int. 2008. Vol. 21. P. 293–303.
34. Girlanda R., Kirk A.D. Frontiers in Nephrology: Immu- ne Tolerance to Allografts in Humans // J. Am. Soc. Ne-
35. phrol. 2007. Vol. 18. P. 2242–2251.
36. Holt A.P., Salmon M., Buckley C.D., Adams D.H. Immu-
37. ne interactions in hepatic fibrosis or «Leucocyte-stro- malinteractions in hepatic fibrosis» // Clin. Liver Dis. 2008. Vol. 12 (4). P. 861–885.
38. Kawai T., Cosimi A.B., Spitzer T.R. et al. HLA-Mismat- ched renal transplantation without maintenance immu- nosuppression // NEJM. 2008. Vol. l4 (358). P. 353–361.
39. Kirk A.D., Hale D.A., Mannon R.B. et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtu- zumab (Campath-1H) // Transplantation. 2003. Vol. 76 (1). P. 120–129.
40. Krams S.M., Martinez O.M. Epstein Barr virus, rapa- mycin, and host immune responses // Curr. Opin Organ Transplant. 2008. Vol. 13 (6). P. 563–568.
41. Letourneau S., Krieg C., Pantaleo G., Boyman O. IL- 2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets // J. Allergy. Clin. Immunol. 2009. Vol. 123. P. 758–762.
42. Li X.C., Turka L.A. An update on regulatory T cells in transplant tolerance and rejection // Nat. Rev. Nephrol. 2010. Vol. 6. P. 577–583.
43. Libby P., Pober J.S. Chronic rejection. Immunity. 2001. Vol. 14. P. 387–397.
44. Magee J.C. Graft fibrosis in stable pediatric liver trans- plant recipients: What does it mean? // Hepatology. 2009. Vol. 49 (3). P. 726–728.
45. Martinez O.M., Rosen H.R. Basic concepts in transplant immunology // Liver Transplantation. 2005. Vol. 11 (4). P. 370–381.
46. Mazariegos G.V. Immunosuppression withdrawal after liver transplantation: what are the next steps? // Trans- plantation. 2011. Vol. 91. P. 697–699.
47. Morelli A.E., Larregina A.T. Apoptotic cell-based thera- pies against transplant rejection: role of recipient’s dend- ritic cells // Apoptosis. 2010. Vol. 15. P. 1083–1097.
48. Movahedi Z., Holt C.D., Saab S. Liver transplant: a pri- mer // Experimental and Clinical Transplantation. 2010. Vol. 8 (2). P. 20–25.
49. Natarajan S., Thomson A.W. Tolerogenic dendritic cells and myeloid-derived suppressor cells: potential for re- gulation and therapy of liver auto- and alloimmunity // Immunobiology. 2010. Vol. 215 (9–10). P. 698–703.
50. Nath D.S., Basha H.I., Mohanakumar T. Anti-human leukocyte antigen antibody induced autoimmunity:role in chronic rejection // Curr Opin Organ Transplant. 2010. Vol. 15 (1). P. 16–20.
51. Pearl J.P., Parris J., Hale D.A. et al. Immunocompe- tent T-cells with a memory-like phenotype are the do- minant cell type following antibody-mediated T-cell depletion // Am. J. of Transplantation. 2005. Vol. 5. P. 465–474.
52. Pham P-T., Lipshutz G.S., Kawahji J., Singer J.S. The evolving role of alemtuzumab (Campath-1H) in renal transplantation // Drug Design, Development and Thera- py. 2009. Vol. 3. P. 41–49.
53. Reding R., Gras J., Truong D.Q. et al. The Immunolo- gical monitoring of alloreactive responses in liver trans- plant recipients:a review // Liver Transplantation. 2006. Vol. 12. P. 373–383.
54. Riley J.L., June C.H., Blazar B.R. Human T regulatory cells as therapeutic agents: take a billionor so of these and call me in the morning // Immunity. 2009. Vol. 30 (5). P. 656–665.
55. Rostaing L., Kamar N. mTOR inhibitor/proliferation sig- nal inhibitors: entering or leaving the field? // J. Nephrol. 2010. Vol. 23 (2). P. 133–142.
56. Sampaio E.L., Freitas T.V., Galante N.Z. et al. Alem- tuzumab induction in kidney transplant recipients // J. Bras. Nefrol. 2010. Vol. 32. P. 89–97.
57. Sanchez–Fueyo A., Strom T.B. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs // Gastroenterology. 2011. Vol. 140. P. 51–64.
58. Schwartz M., Cohen I.R. Autoimmunity can benefit self-maintenance // Immunol Today. 2000. Vol. 21 (6). P. 265–268.
59. Seetharam A., Tiriveedhi V., Mohanakumar T. Alloim- munity and autoimmunity in chronic rejection // Curr. Opin Organ Transplant. 2010. Vol. 15 (4). P. 531–536.
60. Sewgobind V.D., van der Laan L.J., Kho M.M. et al. The calcineurin inhibitor tacrolimus allows the induc- tion of functional CD4CD25 regulatory T-cells by rabbit anti-thymocyte globulins // Clin. Exp. Immunol. 2010. Vol. 161 (2). P. 364–377.
61. Spada M., Riva S., Maggiore G. et al. Pediatric liver transplantation // World J. Gastroenterol. 2009. Vol. 14– 15 (6). P. 648–674.
62. Starzl T.E., Lakkis F.G. The Unfinished legacy of liver transplantation: emphasis on immunology // Hepatology. 2006. Vol. 43. P. 151–163.
63. Starzl T.E. Chimerism and tolerance in transplantation // PNAS. 2004. Vol. 101 (2). P. 14607–14614.
64. Strick-Marchand H., Masse G.X., Weiss M.C., Di San- to J.P. Lymphocytes support oval cell-dependent liver regeneration // The Journal of Immunology. 2008. Vol. 181. P. 2764–2771.
65. Tao R., Hancock W.W. Regulating regulatory T-cells to achieve transplant tolerance // Hepatobiliary Pancreat Dis Int. 2007. Vol. 6. P. 348–357.
66. Waid T.H., Thompson J.S., Siemionow M.S., Brown A. T10B9 monoclonal antibody: A short-acting nonstimu- lating monoclonal antibody that spares γδ T-cells and treats and prevents cellular rejection // Drug Design, De- velopment and Therapy. 2009. Vol. 3. P. 205–212.
67. Wiesner R.H., Demetris A.J., Belle S.H. et al. Acu- te hepatic allograft rejection: incidence, risk factors, and impact on outcome // Hepatology. 1998. Vol. 28. P. 638–645.
Рецензия
Для цитирования:
Артамонов С.Д., Великий Д.А., Онищенко Н.А., Крашенинников М.Е., Иванов И.М., Башкина Л.В., Никольская А.О. СОВРЕМЕННАЯ ТАКТИКА ИММУНОСУПРЕССИВНОЙ ТЕРАПИИ КАК СПОСОБ ФОРМИРОВАНИЯ ТОЛЕРОГЕННОЙ СТРАТЕГИИ ОРГАНИЗМА (НА ПРИМЕРЕ ТРАНСПЛАНТАЦИИ ПЕЧЕНИ). Вестник трансплантологии и искусственных органов. 2012;14(2):98-109. https://doi.org/10.15825/1995-1191-2012-2-98-109
For citation:
Artamonov S.D., Velikiy D.A., Onischenko N.A., Krasheninnikov M.E., Ivanov I.M., Bashkina L.V., Nikolskaya A.O. THE MODERN IMMUNOSUPPRESSIVE TACTICS AS A WAY FOR INDUCING OF TOLEROGENIC STRATEGY AFTER LIVER TRANSPLANTATION (ANALYSIS OF THE PROBLEM STATUS). Russian Journal of Transplantology and Artificial Organs. 2012;14(2):98-109. (In Russ.) https://doi.org/10.15825/1995-1191-2012-2-98-109
Просмотров: 1485
Послать статью по эл. почте 